Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced the additional listing of 10,251,543 newly issued common shares resulting from a stock dividend, with the listing scheduled for April 16, 2025. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Listing Completion and Final Total Outstanding…

Read More “[Disclosure] Celltrion (068270) – Additional Listing (Stock Dividend) / 2025-04-11” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued an advance notice disclosing that it plans to announce its Q1 2025 financial results (covering Jan 1, 2025 – Mar 31, 2025) on April 23, 2025. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verifying Earnings…

Read More “[Disclosure] Samsung Biologics (207940) – Advance Notice of Financial Results Announcement / 2025-04-09” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion decided to acquire 589,276 treasury common shares worth approximately KRW 100.0B through on-market purchases to stabilize its stock price and enhance shareholder value, with plans to retire all acquired shares after completion. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint)…

Read More “[Disclosure] Celltrion (068270) – Treasury Share Acquisition Decision / 2025-04-03” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion decided through a board resolution to retire 268,385 treasury common shares (book value of approximately KRW 45.2B) to stabilize its stock price and enhance shareholder value, with the retirement scheduled for April 18, 2025. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key…

Read More “[Disclosure] Celltrion (068270) – Share Retirement Decision / 2025-04-02” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced a modification of listing to reduce 1,101,379 common shares following a share retirement, decreasing the total outstanding common shares to 213,006,740 shares, effective April 7, 2025. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Registration of Share Count…

Read More “[Disclosure] Celltrion (068270) – Modification of Listing (Share Retirement) / 2025-04-02” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion passed the Part 1 review (clinical design evaluation) for its Phase 3 Clinical Trial Application (CTA) for CT-P44, a Darzalex biosimilar candidate, from the European Medicines Agency (EMA). 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Final…

Read More “[Disclosure] Celltrion (068270) – Approval of Part 1 Clinical Trial Application for Phase 3 Trial of CT-P44 (Darzalex Biosimilar) in Europe / 2025-04-01” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary At Alteogen’s 17th Annual General Meeting of Shareholders, all six proposed agenda items were approved as originally submitted, including the approval of financial statements, the re-election of CEO Soon Jae Park, the new appointment of Vice President Sang Lak Choi as Inside Director, and the approval…

Read More “[Disclosure] ALTEOGEN (196170) – Results of General Shareholders Meeting / 2025-03-31” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure to announce the contract end date as March 31, 2025, following the completion of performance under its pharmaceutical contract manufacturing agreement with Cilag GmbH International. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2025-03-31” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen is holding a domestic Non-Deal Roadshow (NDR) in Seoul from April 8 to April 10, 2025, for domestic and foreign institutional investors to present the status of licensed technology deals and long-term growth strategies. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key…

Read More “[Disclosure] ALTEOGEN (196170) – Investor Relations (IR) Holding / 2025-03-26” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen submitted its audit report audited by Samil PricewaterhouseCoopers with ‘Unqualified’ opinions for both consolidated and separate financial statements, successfully turning both operating income and net income into profitability. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Confirmation of Turnaround…

Read More “[Disclosure] ALTEOGEN (196170) – Submission of Audit Report / 2025-03-21” »